Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
0.6264
+0.0093 (1.51%)
At close: Nov 18, 2025, 4:00 PM EST
0.6264
0.00 (0.00%)
After-hours: Nov 18, 2025, 4:10 PM EST
Rallybio Revenue
Rallybio had revenue of $212.00K in the quarter ending September 30, 2025, a decrease of -29.10%. This brings the company's revenue in the last twelve months to $674.00K, up 12.71% year-over-year. In the year 2024, Rallybio had annual revenue of $636.00K.
Revenue (ttm)
$674.00K
Revenue Growth
+12.71%
P/S Ratio
41.05
Revenue / Employee
$26,960
Employees
25
Market Cap
26.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 636.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RLYB News
- 12 days ago - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 7 weeks ago - Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
- 2 months ago - Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program - Business Wire
- 3 months ago - Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 4 months ago - Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
- 4 months ago - Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - Business Wire
- 5 months ago - Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
- 6 months ago - Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates - Business Wire